Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.

Katz, Eva G; Hauber, Brett; Gopal, Srihari; Fairchild, Angie; Pugh, Amy; Weinstein, Rachel B; Levitan, Bennett S

Katz, Eva G; Hauber, Brett; Gopal, Srihari; Fairchild, Angie; Pugh, Amy; Weinstein, Rachel B; Levitan, Bennett S.

Afiliación

Katz EG; Janssen Research & Development, LLC, Raritan, NJ.
Hauber B; RTI Health Solutions, Research Triangle Park, NC.
Gopal S; Janssen Research & Development, LLC, Titusville, NJ.
Fairchild A; RTI Health Solutions, Research Triangle Park, NC.
Pugh A; The University of California, San Francisco (UCSF), CA, USA.
Weinstein RB; Janssen Research & Development, LLC, Titusville, NJ.
Levitan BS; Janssen Research & Development, LLC, Titusville, NJ.

Patient Prefer Adherence ; 10: 2127-2139, 2016.

Article en En | MEDLINE | ID: mdl-27799749

Palabras clave

benefitrisk assessment; long-acting injectable; patient preference; physician preference; schizophrenia; survey

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Patient Prefer Adherence Año: 2016 Tipo del documento: Article Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google